 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- || Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, Combination therapy: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Feb 1, 2017
P2, N=200, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2018 --> Feb 2019
- | Rituxan (rituximab) / Roche
Enrollment closed: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jan 23, 2017
P2, N=345, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2018 --> Feb 2019 Recruiting --> Active, not recruiting
- |||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 3, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Oncaspar liquid (pegaspargase) / Servier
Clinical: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Aug 30, 2016
P3, N=5437, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P2 trial: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 23, 2016
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2016
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2019 --> Jul 2021
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Jul 28, 2016
P2, N=110, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2019 --> Jul 2021 Recruiting --> Active, not recruiting
- ||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Enrollment closed, Combination therapy: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Jul 28, 2016
P2, N=200, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jul 25, 2016
P2, N=148, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- || Oncaspar liquid (pegaspargase) / Servier
Trial primary completion date: AALL08P1: Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=165, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jun 2014 --> Jun 2013
- || Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Trial primary completion date: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=166, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2014 --> Jun 2013 Trial primary completion date: Sep 2014 --> Feb 2011
- alisertib (MLN8237) / Puma
Enrollment closed, Enrollment change, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - May 11, 2016
P1/2, N=9, Active, not recruiting, Sponsor: Thomas Jefferson University
Trial primary completion date: Sep 2014 --> Feb 2011 Recruiting --> Active, not recruiting | N=43 --> 9
- || Oncaspar liquid (pegaspargase) / Servier
Trial primary completion date: AALL08P1: Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=165, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=43 --> 9 Trial primary completion date: Mar 2015 --> Jun 2014
- Trial primary completion date: Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 19, 2016
P2, N=80, Active, not recruiting, Sponsor: Stanford University
Trial primary completion date: Mar 2015 --> Jun 2014 Trial primary completion date: May 2015 --> Mar 2017
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 28, 2016
P2/3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Mar 2017 Phase classification: P3 --> P2/3
- ||| prednisone delayed-release tablet / Generic mfg.
Trial completion, Observational data, Enrollment change, Trial primary completion date: SUNRAY: A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=75, Completed, Sponsor: Horizon Pharma Ireland, Ltd., Dublin Ireland
Phase classification: P3 --> P2/3 Enrolling by invitation --> Completed | N=60 --> 75 | Trial primary completion date: Feb 2016 --> Oct 2015
- | prednisone delayed-release tablet / Generic mfg.
New P4 trial: Delayed Release Prednisone in PMR (clinicaltrials.gov) - Mar 9, 2016
P4, N=45, Recruiting, Sponsor: Dinora, Inc.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, IO biomarker: Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) (clinicaltrials.gov) - Mar 7, 2016
P2, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Completed | N=60 --> 75 | Trial primary completion date: Feb 2016 --> Oct 2015 Trial primary completion date: Jan 2017 --> Jan 2018
- || Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, Combination therapy: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Feb 2017 --> Feb 2018
- || prednisone delayed-release tablet / Generic mfg.
Observational data, Trial primary completion date: SUNRAY: A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=60, Enrolling by invitation, Sponsor: Horizon Pharma Ireland, Ltd., Dublin Ireland
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Jul 2015 --> Feb 2016
- |||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 21, 2016
P2, N=92, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2015 --> Feb 2016 Active, not recruiting --> Recruiting
- ||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 19, 2016
P2, N=92, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment change, Combination therapy, Metastases: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Dec 31, 2015
P1/2, N=69, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=95 --> 69
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 29, 2015
P3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
N=95 --> 69 Active, not recruiting --> Completed
- veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 23, 2015
P2, N=148, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Mar 2013 --> Dec 2015
- veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Enrollment closed, Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 14, 2015
P2, N=148, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2013 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2013
- veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 10, 2015
P2, N=148, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2013 Trial primary completion date: Dec 2015 --> May 2016
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=345, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> May 2016 Suspended --> Recruiting
- ||| nelarabine / Generic mfg.
Enrollment change, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 22, 2015
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting N=60 --> 100 | Trial primary completion date: Jul 2016 --> Jul 2017
- Trial completion, Enrollment change, Trial primary completion date: Timed Release Tablet Prednisone in Polymyalgia Rheumatica (clinicaltrials.gov) - Sep 9, 2015
P2/3, N=12, Completed, Sponsor: University Hospitals Bristol NHS Foundation Trust
N=60 --> 100 | Trial primary completion date: Jul 2016 --> Jul 2017 Active, not recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Jul 2011 --> Nov 2010
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P1/2 trial, Metastases: c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=39, Recruiting, Sponsor: OHSU Knight Cancer Institute
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 12, 2015
P3, N=63, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Jul 2011 --> Nov 2010 N=195 --> 63 | Trial primary completion date: Sep 2015 --> Dec 2014
- || prednisone delayed-release tablet / Generic mfg.
New P3 trial: GWIIRT: Gulf War Illness Inflammation Reduction Trial (clinicaltrials.gov) - Jul 23, 2015
P3, N=100, Recruiting, Sponsor: Minneapolis Veterans Affairs Medical Center
- Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 16, 2015
P2, N=92, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=195 --> 63 | Trial primary completion date: Sep 2015 --> Dec 2014 Not yet recruiting --> Recruiting
- prednisone delayed-release tablet / Generic mfg.
Trial completion, Trial primary completion date: Efficacy of Lodotra (clinicaltrials.gov) - Jul 8, 2015
P4, N=147, Completed, Sponsor: Mundipharma Korea Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: May 2014 --> Apr 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial primary completion date: May 2014 --> Apr 2015 Trial primary completion date: May 2015 --> Jan 2018
- veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial primary completion date, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=148, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Jan 2018 Trial primary completion date: Jun 2015 --> Dec 2015
- peripheral blood stem cell transplantation / National Cancer Institute
Clinical: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=85, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Suspended
- ||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 8, 2015
P2, N=92, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| apatorsen (OGX-427) / Achieve Life Sciences
Trial completion, Metastases: OGX-427 in Castration Resistant Prostate Cancer Patients (clinicaltrials.gov) - May 6, 2015
P2, N=74, Completed, Sponsor: British Columbia Cancer Agency
Recruiting --> Suspended Active, not recruiting --> Completed
- ||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 20, 2015
P2, N=80, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Trial primary completion date, IO biomarker: Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) (clinicaltrials.gov) - Apr 15, 2015
P2, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=80 --> 60 | Trial primary completion date: Jan 2015 --> Jan 2017
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment open: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Mar 20, 2015
P3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
N=80 --> 60 | Trial primary completion date: Jan 2015 --> Jan 2017 Not yet recruiting --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 28, 2015
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
P3 data: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jan 26, 2015
P3, N=600, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Dec 2014 --> Apr 2015
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 18, 2015
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 5, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Aug 2014 --> Jan 2015
- prednisone delayed-release tablet / Generic mfg.
Observational data: SUNRAY: A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 10, 2014
P=N/A, N=60, Enrolling by invitation, Sponsor: Horizon Pharma Ireland, Ltd., Dublin Ireland
- melphalan / Generic mfg., lenalidomide / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Sep 16, 2014
P3, N=307, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2014 --> Jan 2015 Trial primary completion date: Oct 2014 --> Jan 2014